Back to Search Start Over

Review of immune-related adverse events in prostate cancer patients treated with ipilimumab: MD Anderson experience.

Authors :
Gao, J
He, Q
Subudhi, S
Aparicio, A
Zurita-Saavedra, A
Lee, D H
Jimenez, C
Suarez-Almazor, M
Sharma, P
Source :
Oncogene. 10/22/2015, Vol. 34 Issue 43, p5411-5417. 7p.
Publication Year :
2015

Abstract

Targeting a T-cell inhibitory checkpoint with the anti-CTLA-4 monoclonal antibody, ipilimumab, represents a scientific breakthrough in immunotherapy for the treatment of cancer. However, ipilimumab therapy is also associated with unique side effects, known as immune-related adverse events (irAEs), which need to be recognized and managed with immunosuppressive agents. To date, the majority of our knowledge regarding ipilimumab-associated side effects is based upon clinical studies in melanoma. Here we provide a review of ipilimumab-induced irAEs and our experience in a cohort of 44 patients with prostate cancer who were treated at the MD Anderson Cancer Center on two different clinical trial protocols. [ABSTRACT FROM AUTHOR]

Details

Language :
English
ISSN :
09509232
Volume :
34
Issue :
43
Database :
Academic Search Index
Journal :
Oncogene
Publication Type :
Academic Journal
Accession number :
110459437
Full Text :
https://doi.org/10.1038/onc.2015.5